Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04024800
Title Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Antigen Express, Inc
Indications

triple-receptor negative breast cancer

Therapies

AE37 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.